NDATOPICALGEL
Approved
Aug 2013
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
5/8 — Partial
MIRVASO (brimonidine tartrate) by Galderma is alpha-2 adrenergic agonist. First approved in 2013.
Drug data last refreshed 10h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIRVASO is a topical gel formulation of brimonidine tartrate, an alpha-2 adrenergic agonist approved in 2013 for reducing facial erythema (redness) associated with rosacea. Applied directly to affected skin, it works through direct vasoconstriction to provide symptomatic relief. The product addresses a dermatological aesthetic concern with a non-systemic mechanism.
$0.9MPart D
PeakStable
4.7 years to LOEProduct is in peak commercial stage with modest Part D utilization; team size likely stable with focus on market maintenance rather than expansion.
Mechanism of Action
alpha-2 adrenergic agonist. Topical application of MIRVASO topical gel may reduce erythema through direct vasoconstriction.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness
Started May 2025
578 enrolled
Ocular Redness
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
Started Apr 2023
512 enrolled
Allergic Conjunctivitis
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis
Started Nov 2022
229 enrolled
Seasonal Allergic Conjunctivitis
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis
Started Oct 2022
188 enrolled
Allergic Conjunctivitis
"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"
Started May 2022
380 enrolled
Ocular Redness
Worked on MIRVASO at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.